Navigation Links
New Anal Cancer Therapy Fails to Improve Outcomes
Date:4/22/2008

Experimental use of cisplatin no better than standard treatment, researchers say

TUESDAY, April 22 (HealthDay News) -- Compared to the standard treatment regimen for anal canal cancer, the use of the chemotherapy drug cisplatin before other treatments didn't improve disease-free survival and resulted in a higher rate of colostomy procedures, says a U.S. study.

Currently, the preferred primary therapy for patients with anal canal cancer is chemoradiation (concurrent use of radiation and the anti-cancer drugs fluorouracil/mitomycin), which achieves a five-year survival rate of about 65 percent, according to background information in the study.

It's been suggested that reducing cancer in the primary tumor and in the lymph node or nodes prior to chemoradiation might improve disease-free survival. Pilot studies using cisplatin prior to chemoradiation showed promise.

In this new, randomized controlled trial, Dr. Jaffer A. Ajani, of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues compared treatment with fluorouracil plus mitomycin and radiation therapy to treatment with fluorouracil plus cisplatin and radiation therapy.

The findings from 644 patients showed a five-year, disease-free survival rate of 60 percent in the mitomycin group and 54 percent in the cisplatin group. The five-year overall survival rate was 75 percent in the mitomycin group and 70 percent in the cisplatin group. There were more cancer-related deaths in the cisplatin group (54) than in the mitomycin group (28).

The five-year, local-regional cancer recurrence and distant metastasis rates were 25 percent and 15 percent, respectively, for the mitomycin group and 33 percent and 19 percent, respectively, for the cisplatin group. Severe blood toxicity was worse in the mitomycin group. The cisplatin group had a higher rate of colostomy (19 percent vs. 10 percent).

"The question remains how to further improve disease-free and colostomy-free survival relative to the continued standard of concurrent chemoradiation with fluorouracil and mitomycin," the study authors wrote. "Options to explore included targeted agents (e.g., results with concurrent cetuximab plus radiation for head/neck cancer), dose escalation with intensity-modulated radiation plus concurrent chemotherapy, and surgical excision of residual cancer after concurrent chemoradiation at an earlier interval, when sphincter preservation may still be feasible in select patients."

The study was published in this week's issue of the Journal of the American Medical Association.

More information

The American Cancer Society has more about anal cancer.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, April 22, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Scientists discover a mechanism that can send cells on the road to cancer
2. Factors in Cancer Death Rates Stay Stagnant
3. Cancer Death Rates Stay Stagnant
4. OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
5. Phone counseling improves quality of life, immune systems of cervical cancer survivors
6. Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
7. A stem cell type supposed to be crucial for angiogenesis and cancer growth does not exist?
8. Potential viral therapy weapon for difficult cancers is safe and effective in study
9. American Cancer Society report details cancer prevention efforts
10. Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
11. Cancer cells spread by releasing bubbles, according to an MUHC study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
(Date:5/26/2017)... MA (PRWEB) , ... May 26, 2017 , ... On ... Act (AHCA), which narrowly passed the U.S. House on May 4, would result in ... be expected under continued implementation of the 2010 Patient Protection and Affordable Care Act ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
(Date:5/26/2017)... ... 2017 , ... “Cactus Jack: Against All Odds”: the story of Coach Cactus ... Against All Odds” is the creation of published author, Walter Hubbard, a retired wildlife ... Carlisle’s third child Jane. Walter. Walter and Jane have three adult children and ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Altec ... participation in nVerge 2017 – a one-day technology conference in San Diego, CA. ... solution, which allows users to fully utilize and enhance their Sage ERP solutions by ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... -- Global Health Intelligence (GHI), the leading healthcare ... published its 2017 ranking of the Best-Equipped Hospitals in ... analysis from GHI,s hospitals database for Latin America , ... The GHI database covers 86% of the hospitals in ... points for each institution in key areas such as beds, ...
(Date:5/9/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... it has earned a spot on Forbes, ... was ranked among 500 U.S. employers as well as ... and Services. The annual Forbes ... survey of over 30,000 employees across 25 industries. The ...
(Date:5/8/2017)... NEW YORK , May 8, 2017 ... in the transition from fee for service reimbursement. Black ... April 2017. 1.       The Market for ... 77% of physician practices with 3 or ... Compliance Technology Solutions by Q4. "Given the magnitude of ...
Breaking Medicine Technology: